My name is Muhammad Shahbaz. I am from Pakistan. I am currently a master’s degree student, and my major is general surgery. I have been studying at Shandong University for the last 8 years. I am studying on CSC scholarship and I was awarded excellent graduate in 2011. During the study time at Shandong University, I was awarded the excellent student each year. Under the supervision of my tutor & mentor Prof. Niu Jun I have learned surgical skills and have actively participated in academic research work.
I also have learned Chinese language well during those years in China. I am the founder of a Charity Organization IECO (International Education Charity Organization). My stories were covered by Qilu Newspaper and Shandong Education TV. I was awarded from Jinan Municipal Government as excellent volunteer consecutively for last two years. I would like to be an academic surgeon in future.
During those years in China, I have also chaired the seminar for the junior students and have taught them about the research and clinical studies and how to pass the medical license exams of different countries. Three of my articles have been published in the China Daily Website, China Daily Website (Shandong Province) and My China Story, also a number of articles about my study life have been published on Shandong University Website.
Life means everything for us. And disease is the opposite of life. When we talk about disease, we are thinking of something against our health. We have spent and are spending much more money on medical research. Millions of people have been affected and are being affected every year. There are thousands of diseases. For hundreds of them, we have found cures via continuous striving in research. Scores of them are dangerous. A few of them are fatal. While we are thinking about the most dangerous diseases the first name that comes to mind is Cancer.
Since the mid-20th century, billions of dollars have been spent on cancer research and millions of research papers have been published on cancer. But the percentages of success have improved fractionally. The Chinese government is spending a lot of money on cancer research. On December 23, 1971, U.S. President Richard Nixon signed the National Cancer Act and declared “war on cancer” to amend the Public Health Service Act so as to strengthen the National Cancer Institute and more effectively carry out the national effort against cancer.
Every year, about15 million new cases of cancer appear, and 10 million people die of it around the world. We can either avoid and prevent the cancer or treat it. By now we have different methods of treatment of cancer, which are chemotherapy, immunotherapy, radiation therapy, surgery, adjuvant therapy, and transplantation. The main purpose of our research team was to find methods to make the treatment more effective, such as targeted therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival. We tried to explore the precise information about the role that targeted therapies play in precision medicine and how targeted therapies work against cancer, who receives targeted therapies, common side effects, and what to expect when having targeted therapies.
The main members our team, including Liang Benjia, Gao Huijie, Fang Ruliang, Zhang Jia, Wu Junben, Niu Zhengchuan , Peng Cheng and myself, conducted the research under the supervision of Prof. Niu Jun. Prof. Niu has been working on novel and exciting research for the last two decades.
Last year, our team published eight SCI research papers with total impact factor of 30. I have published three SCI papers as first co-author and one SCI paper as second author with IF of 8.2. The motivation to perform this research was given by my mentor Prof. Niu Jun and some of the senior students.
From the very beginning of my undergraduate studies I started reading research papers, writing simple research and collecting data. After starting my master’s degree work, I was on the right path as Prof. Niu guided me and also broadened my viewpoint.
I still remember the year 2008, I was in the third year undergraduate MBBS program and the fellows in our class were taking the rabbits out of the cage. We were to observe the role of the arterial chemoreceptors and baroreceptors in the circulatory response to hypoxia of the rabbits. We used cell culture, RT-PCR techniques, Western blotting and immunohistochemistry, all the techniques I studied in my undergraduate years and later performed more specifically in postgraduate studies.
During my third year undergraduate studies I was curious to learn more research techniques and I also kept on attending international conferences. The first such a conference I attended in 2007, was the 21st International Congress of Lymphology and Oncology, where I presented research concerning patients having upper limb lymphoedema after breast cancer surgery. In the coming years I learned the knowledge about lymphology and oncology. In 2009 I attended the 22nd International Conference of Lymphology and Oncology and I won the best young scientist speaker award. I started to learn the research techniques more comprehensively, feeding the mice every day, changing the culture medium at the right time even in the holidays and systematically performing the tests, because delaying one step or getting one step late meant the whole procedure was disturbed and could have effects on the final results. So in order to avoid negative results we made sure that we can take care of mice and rabbits.
There is a famous saying that “I can have cancer but the cancer cannot have me”. In the process to find new methods of treatment and make the existing methods of treatment more effective, we conducted the research on a variety of cancers, which were mainly pancreatic cancer and colon cancer
I joined our research team in the second year of my postgraduate studies in 2013 and we comprehensively conducted novel research about targeted therapy. I will discuss in detail the targeted therapy of our main research. The title of our research was “Integrinβ6-targeted Immunoliposomes Mediate Tumor Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma”. It was published in the Clinical Cancer Research Journal in December, 2014, with SCI impact factor of 8.2. The other research articles by our team are "Comparison of the BISAP scores for predicting the severity of acute pancreatitis in Chinese patients according to the latest Atlanta classification” (SCI IF 2.2); “mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer” (SCI IF 1.2); “Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells” (SCI IF 0.5).
There are different kinds of ways we can contribute to scientific society. One is basic research, the second is translational medicine, and the third one is clinical research. The successful application of each method can improve the prognosis of disease. And we can also put different methods of treatment together in the form of adjuvant therapy to increase the efficacy of the treatment.
Colon cancer is the third most common cancer and the fourth-leading cause of cancer deaths worldwide. Although surgery remains the preferred treatment, 5-fluorouracil (5-FU)-based adjuvant chemotherapy is the conventional care for stage III (lymph node-positive) patients and can reduce mortality 25% compared with surgery alone. However, because the response rate of chemotherapy is only 10–20%, the treatment of advanced and metastatic cases remains a challenging problem. Therefore, it is urgent to explore novel therapeutic strategies for colon cancer treatment to overcome chemotherapeutic drug resistance and to improve chemotherapeutic efficacy.
The targeted delivery of anticancer drugs to tumors has been broadly recognized as an important method for improving chemotherapeutic efficacy and attenuating chemotherapeutic side effects. Sterically stabilized liposomes with a polymeric PEG coating, which have prolonged circulation times, lower reticuloendothelial system (RES) uptake and higher tumor accumulation, were thought to be an ideal drug delivery system. However, these liposomes passively interact with tumor cells, in vitro or in vivo, resulting in non-specific drug release that leads to the eventual diffusion of the drugs into some normal tissues or cells rather than tumors.
Immunoliposomes (ILs), which are conjugated with monoclonal antibodies (mAbs), are capable of both drug delivery and molecular targeting. By combining the specific targeting properties of mAbs and the drug delivery advantages of liposomes, ILs are a promising approach for the targeted delivery of anticancer drugs to tumors. To date, various tumor-associated antigens have been validated as targets for antibody-based ILs in cancer therapeutics.
ILs targeting CD30, HER2/neu, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR), which are expressed on various tumor cell types, have been developed and thoroughly characterized. Based on encouraging preclinical data and advances in large-scale production processes, EGFR-specific ILs are already being used in clinical trials. Integrinβ6 (ITGB6) is a subtype of integrin that is expressed exclusively on the surfaces of epithelial cells and is a receptor for extracellular matrix (ECM) proteins. ITGB6 expression is up-regulated during embryogenesis, oncogenesis and epithelial repair, whereas it is generally undetectable in healthy epithelial tissues. In colon cancer, ITGB6 is specifically expressed in tumor tissues and is rarely present in tissues adjacent to the tumor.
Additionally, we previously reported that ITGB6 was associated with colon cancer pathology, malignancy and TNM stage and could act as a prognostic indicator in aggressive colon carcinomas. Our research previously confirmed that ITGB6 contributed to chemotherapeutic resistance in colon cancer; ITGB6 protected colon cancer cells from 5-FU-induced growth inhibition and apoptosis. Unsurprisingly, the exclusive expression of ITGB6 and its influential effects in colon cancer make it a novel therapeutic target for colon cancer treatment. ITGB6 has previously been employed as a clinical biomarker for early cancer detection.
Moreover, ITGB6 signaling axis-blocking agents have also been designed to exploit this receptor as a therapeutic target for cancer treatment. However, research concerning ITGB6 targeted drug delivery for colon cancer chemotherapy has not been reported. In the present study, we describe the design, preparation, and characterization of ITGB6-targeted ILs, and explore their antitumor efficiency against colon cancer in vitro and in tumor xenograft models using 5-FU loaded ITGB6-targeted ILs. The Translational Relevance of our research is that this study described a targeted drug delivery system for highly efficient and selective delivery of anticancer drugs in colon cancer overexpressing ITGB6. The ITGB6-targeted ILs achieved favorable antitumor efficacy and insignificant systemic toxicity, followed by specific binding and internalization in colon cancer cells.
As a result, this approach may be useful for the delivery of various drugs for enhanced therapeutic index against colon cancer. Moreover, because ITGB6 is also specifically expressed in a variety of epithelial carcinomas, ITGB6-targeted ILs may represent a potential strategy for the clinical treatment of additional cancers.
In my first year working towards my Master’s degree, besides learning subjects in basic theory I followed Prof. Niu Jun in the out-patient department and in the operation theater. I learned a number of surgical techniques including laparoscopic surgery, cholecystectomy, gastrectomy, whipple operation and thyroidectomy. Here I would like to mention one emotional story that I have mentioned in my story in the China Daily Website.
There were tears in my eyes, as the young girl told Professor Niu Jun, “Wo tong guo le,” which means “I passed the exam.” One month before, Sir. Niu Jun had told the patient, “You can participate in the Gaokao,” and it was the whole team of our General Surgery department headed by Prof. Niu Jun celebrating the happiness that we successfully operated on the seventeen years old girl with thyroid cancer metastasized to the lungs. She wanted to take the exam; it was on June 7, 2013. She had been admitted to our ward on May 15th. She had the option to come after the exam, or operate; however, as the cancer could spread to other parts of her body if she chose a later date, she opted to go for operation, to be done on May 20th. The successful surgery was done and she was able to speak within a few days of operation. She was discharged from hospital on May 27th, ten days before the exam.
Visiting L’Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD), France, was also a great experience to learn about innovation, precision and minimally invasive surgery and robotic surgery. In April, 2007 Prof. Jacques was one of the surgeons of the team who successfully performed scarless surgery, also called as NOTES (Natural Orifice Translumenal Endoscopic Surgery); in this kind of surgery we approach the diseased part from the natural opening of human body, e.g. the mouth, or a anus, to resect the diseased organ and remove it through the natural opening. The technique was brought to China and the first such kind of operation was performed by a team of surgeons, gynecologists, and gastroenterologists headed by Prof. Niu Jun in 2009. I feel it my honor to learn minimally invasive surgery and modern precision surgery from the two best surgeons in the world.
The IHU Strasbourg and the IRCAD are unique facilities to learn modern techniques of modern surgery and operations. The future is based on known success. It was taught to me during a meeting with a professor. The new challenge in the modern medicine field is that our enemies (virus, bacteria and pathogens) are getting stronger and stronger and have gotten resistance against the drugs; and the diseases have become more severe and complicated while new infectious diseases and viruses erupt and are evolving with the modernization of human society.
In the modern era, precision surgery has evolved too. The visible patient is an original user-friendly online service for physicians who need a personalized 3D modelling of a patient to plan therapy efficiently, a project where we can use the CT, MRI, PACS scans of the patients to compile and combine them together using novel software to get the virtual 3D view of patients’ anatomy and internal organs. This can be used intraoperatively for planning the right surgical procedure and is beneficial and convenient for both doctors and patients. The use of Google glasses in advanced precision surgery and ultramodern computer software for the diagnostic imaging of the internal organs can also be used for the real time tracking of skin deformation, simulation of organ deformation and real time laparoscopic image analysis.
During my visit to IRCAD for training, I felt immense happiness to explore and learn about the modern techniques of diagnosis and treatment of diseases especially cancer. The future of surgery will be based on the image guided surgery via use of the techniques of virtual patients, preoperative simulation, intraoperative assistance, and combining augmented reality and robotics.
In the end I would like to acknowledge and pay my special thanks and regards to my professors, Prof.Niu Jun, Prof.Liu Zhiyu, Prof.Jia Jihui and Prof. Jiang Suhua. And special thanks for my parents, family and friends who helped and encouraged me during all these years. I would also like to encourage my fellows and junior medical students to put hands in hands and work hard; strive to defeat the cancer via every possible way we can.
附译文：
我是穆罕默德•沙哈巴兹。来自巴基斯坦。现在攻读硕士学位，专业是普通外科。我在山东大学学习已经八年了。获得国家留学基金委员会资助，2011年，我曾获得优秀毕业生的殊荣。在山东大学学习期间，每年都获得优秀学生的称号。在我的导师牛军教授的指导下，我已经掌握了一些外科手术相关技巧并且积极参与学术研究工作。
在中国的几年里，我的中文水平有很大的提高。同时我创立了慈善组织IECO（国际教育慈善组织）齐鲁晚报以及山东教育电视台均报道过我的故事。连续两年获得由济南市政府颁发的优秀志愿者称号。未来我想成为一名专业外科医生。
在中国的这些年里，我曾经为本科生主持座谈会，教授他们如何进行调查，临床研究以及通过不同国家的医生资格执照考试。我已经在中国日报网，中国日报网（山东地区），我的中国故事上发表了三篇文章。在山东大学网站上，我也发表了很多关于我学习生活的文章。
生命对于我们来说就是一切，然而疾病威胁着生命。当我们谈及疾病，首先想到的是疾病威胁健康。我们已经而且正花费越来越多的金钱在医学研究上。每年都有数以百万的人感染疾病。疾病千百万种，通过不懈的研究，我们攻克了其中的数百种。疾病中的大部分很危险， 其中有些具有致命威胁。当我们考虑最具危险性的疾病时，首先想到的就是癌症。
自从20世纪中叶以来，在癌症研究方面，花费共计数十亿美元，有数百万关于癌症研究的论文发表。但癌症治愈病例却增长缓慢。中国政府在癌症研究方面投入大量资金。1971年12月23日，为增强美国国家癌症研究所的实力以及更有效的加大抗癌方面国家力度，美国总统尼克松补充了《公共保健服务法》，签署了《国家癌症法案》，向癌症宣战。
全球每年新增大约1500万的癌症病例，其中，约有1000万人死于癌症。面对癌症，我们既不能预防也不能治愈。如今，在癌症治疗方面，我们采用不同的方法，分别是化疗，免疫疗法，放射治疗，手术，辅助治疗以及转移疗法。我们研究组的目标是找到有效治疗癌症的手段，比如说靶向治疗。靶向治疗是采用能干预癌细胞生长以及存活分子的药物。我们尝试探索出在靶向治疗在精确药物中所起的作用，靶向治疗对抗癌症的机理，接受靶向治疗的人群，普遍副作用以及进行靶向治疗的预期效果。
我们小组成员包括梁本甲，高会杰，方汝亮，张嘉，吴俊本，牛正川以及我自己。在牛军教授的指导和监督下进行实验研究。牛教授从事这一新型研究领域已经二十多年。
去年，我们小组在SCI论文上共发表了八篇文章，影响因子共30。我作为第一作者发表了3篇SCI论文，作为第二作者发表了1篇论文，影响因子总共8.2。在完成研究方面，我的导师牛军教授，还有一些高年级学生起到了很好的促进作用。
在本科学习初期，我就开始阅读研究资料，写一些简单的研究报告和收集数据。在开始攻读研究生时，导师牛军教授为我指明方向，开阔了我的眼界。
我仍记得2008年，也就是我攻读临床医学学士的第三年，我和班里的同学用兔子来进行实验。我们观察组织缺氧的兔子体内，循环系统中动脉化学受体和压力感受器的反应。我们运用所有本科学过的技术，包括细胞培养，反逆录酶聚合酶链锁反应，免疫印迹以及免疫组织化学。在稍后的研究生阶段又采用了更为具体的技术。
在本科学习的第三年，我怀着强烈的好奇心学习了更多的研究技术，也坚持参加各种国际性会议。第一次参加的是2007年举行的21世纪淋巴学和肿瘤学国际会议。会上，我发表了关于病人乳腺癌手术术后病发上肢淋巴水肿的研究。过后，我学习了关于淋巴学以及肿瘤学的知识。2009年，我参加了第22届淋巴学和肿瘤学国际会议，荣获最佳青年发言人。我开始更加完善深入的学习研究技术，每天喂养实验室的白鼠。由于耽搁一步就意味着整个实验过程受到干扰，影响试验结果，所以，即时在假期，我都会适时改变培养基环境，有条不紊的进行试验。为了避免结果无效，我们精心照顾实验用白鼠和兔子。
有句话这么说“我会得上癌症，但是癌症不能左右我。”在发现新的治疗方法以及使现有治疗方法更有效的过程中，我们对各种癌症进行研究，专攻胰腺癌和直肠癌。
2013年研二时，我加入了我们的研究团队，我们已经在靶向治疗领域进行了全面研究。我将会对我们主要研究领域-靶向治疗进行细节讨论。我们的研究课题是 “Integrinβ6靶向免疫脂质介导肿瘤特异性药物输送和提高结肠癌疗效。”已于2014年12月发表在临床癌症研究杂志， SCI影响因子8.2 。由我们的团队发表的其他的研究文章是“ BISAP分数与最新亚特兰大分级预测中国急性胰腺炎患者的严重程度的比较” （ SCI IF 2.2 ） ; “生长抑素受体mRNA表达的亚型SSTR -2， SSTR -3和SSTR -5和其在胰腺癌意义” （SCI IF 1.2） ; “基质金属蛋白酶抑制剂MMI- 166抑制SW1990人胰腺癌细胞生长” （ SCI IF 0.5 ）。
如今在促进科学发展上有很多方式。第一种是基本研究，第二种是转化医学，第三种是临床医学。每种方式的成功运用都能改善疾病预断。我们也能结合各种治疗手段，以辅助治疗的方式来提高疗效。
结肠癌是全球范围内发病率第三、致死率第四的肿瘤。尽管手术切除是其主要的治疗方式，以5-氟尿嘧啶为基础的辅助化疗仍然是III期结肠癌传统的治疗方案，与单纯手术相比，术后联合化疗可以降低结肠癌25%的死亡率。但由于化疗的有效率仅为10%—20%，晚期转移性结肠癌的治疗仍然是目前人们面临的严峻挑战。因此，探寻结肠癌治疗的新靶点来克服化疗耐药，提高化疗效果，是亟待解决的问题。
大家一致认为靶向输送抗肿瘤药物是提高化疗效率，减少副作用的重要举措。理想的药物输送系统是：空间结构稳定的脂质体外包裹多聚PEG外壳，延长循环时间，降低网状内皮系统的摄取，增加抗肿瘤药物在肿瘤组织的聚集。但是，这些脂质体在体内和体外均不与肿瘤细胞特异性结合，导致药物在正常组织非特异性地释放。
免疫脂质体是将脂质体与单克隆抗体耦联在一起，对药物的分子靶向输送起到重要作用。将单克隆抗体的特异性与脂质体的载药功能结合在一起，免疫脂质体对抗肿瘤药物的靶向输送有无限应用潜能。目前为止，多种肿瘤相关抗原已被认证为免疫脂质体肿瘤靶向治疗的特异性靶点。
CD30、HER2、表皮生长因子受体（EGFR）、血管内皮生长因子受体（VEGFR）等在多种肿瘤细胞表面均表达，靶向这些分子的免疫脂质体已经被研发，EGFR特异性免疫脂质体已用于临床试验。整合素β6（ITGB6）是整合素家族的亚型，作为细胞外基质蛋白的受体，整合素β6在上皮细胞高表达。在胚胎发育过程、肿瘤形成过程及上皮修复过程之中，ITGB6表达上调，而在正常上皮组织中，β6几乎不表达。β6在结肠癌组织中高表达而在起相邻的癌旁组织几乎不表达。
除此之外，我们前期研究发现，ITGB6的表达与结肠癌的病理类型、恶性程度、TNM分期密切相关，可作为进展期结肠癌独立的不良预后指标。我们证实，ITGB6可以抑制5-氟尿嘧啶诱导的结肠癌细胞生长抑制和凋亡。不难发现，ITGB6在结肠癌中高表达及其对结肠癌的作用使其成为结肠癌靶向治疗的优良靶点。ITGB6前期被用于早期结肠癌的临床生物诊断。
更为重要的是，ITGB6信号传导通路轴的阻断剂已被用于针对该靶点的结肠癌靶向治疗。但是，以ITGB6为靶点的针对结肠癌的化疗药物靶向运输至今仍未见报道。在这次研究中，我们设计并检测了以ITGB6为靶点的免疫脂质体，研究了该脂质体在体外抗结肠癌肿瘤细胞的作用，并通过裸鼠移植瘤模型检测该脂质体对5-氟尿嘧啶化疗效果的作用。该免疫脂质体可以高效并有选择性地将结肠癌化疗药物输送至高表达ITGB6的结肠癌组织中。靶向结合于结肠癌细胞，以ITGB6为靶点的免疫脂质体表现出良好的抗肿瘤效果，且无明显的系统毒副作用。
因此，这种方法可用于多种药物的靶向输送，由此改善了结肠癌的治疗效果。更为重要的是，ITGB6在许多上皮性肿瘤中是高表达的，以ITGB6为靶点的免疫脂质体可为多种上皮性肿瘤的靶向治疗提供有效手段。
在攻读硕士的第一年，除了学习基本知识外，我跟随牛军教授实习于问诊部和手术室。我学到了很多手术技术。包括腹腔镜手术，胆囊切除术，胃切除，惠普尔手术以及甲状腺摘除术。在此，我将讲述一则我曾经在中国日报网上发表过的感人故事。
当这名年轻的女孩对牛军教授说：“我通过了，”也就是我通过考试了时，我热泪盈眶。一个月前，牛教授带领我们外科团队所有成员，向这位17岁女孩手术成功表示祝贺时，牛教授告诉她，“你可以参加高考”。她那时是甲状腺癌转移到肺部，然而她想参加2013年6月7日的高考。本来可以选择考完再来住院做手术，然而，如果她选择晚来住院，那么癌细胞就会扩散到身体其他部位，所以她选择考前的3月15日前来住院，在3月20日进行手术。手术很成功，术后几天便能开口说话，在考试前的5月27日，她出院了。
造访法国消化道癌症研究中心（IRCAD），是学习创新，精确，微创手术以及机器人手术一次难忘的经历。2007年4月，雅克（Jacques）教授，作为手术团队的一员，成功的完成无疤痕手术，也就是NOTE(自然孔道经腔内手术)。在该手术中，我们通过人体自然开口（像是嘴巴或者肛门）来接近病灶，切除患病器官并从自然开口处移除。这门技术引进到中国，第一次取得成功是由牛军教授带领的医生团队实现的。该小组包括外科医生，妇科医生和胃肠病学家。能够跟随在微创手术和现代精密手术方面最优秀的两位外科医生学习，是我的荣幸。
IHU斯特拉斯堡和IRCAD是学习现代外科手术最好的机构。现有的成功铸就辉煌的未来。我知道这一点是在和一次教授的会面上，现代医药领域的全新挑战来自我们的敌人（病毒、细菌和病源）变得越来越强大，具备了抗药性。疾病变得更加可怕和复杂，新型感染疾病和病毒随着人类社会的现代化而爆发、升级。
当今，精准外科手术也取得了进一步的发展。The Visible Patient是一款容易使用的在线服务软件，可以通过绘制关于患者的个性化3D模型来帮助内科医生有效地制定治疗计划。我们可以通过新型软件来编辑和整合患者的CT,MRI以及PACS扫描结果，得到患者的解剖和内脏的3D虚拟影像。这项技术可以应用在手术进行中，指导手术的顺利进行，对于医生和患者，都非常的有用和便捷。精准外科手术中谷歌眼镜的使用以及在内脏诊断影像学中超现代计算机软件的运用，能够完成对于皮肤变形，器官变形的实时追踪以及腹腔镜影像的实时分析。
在IRCAD实习期间，对于能狗研究和学习疾病诊疗，特别是癌症诊疗的现代技术，我感到非常高兴。未来外科手术将建立在通过利用先进技术，即虚拟病人，术前模拟，术中协助，增强现实和机器人技术的结合，形成图象来引导手术进行。
最后，在此，我想对我的教授们表达诚挚的感谢与敬意，包括牛军教授，刘执玉教授，贾继辉老师，姜苏华老师，马凤伟老师和孙鹏程老师。还对这些年来帮助我，鼓励我的父母，家人Misbahul Ferdous, Effat Un Nesa,H.M.Sajjad, Muhammad Ali akbar,Ali Faheem & Muhammad Ijaz， 刘慧以及朋友们表示诚挚的感谢。我也愿意鼓励我的伙伴们以及医学院本科生们团结起来，努力钻研，竭尽全力攻克癌症顽疾。
注：本文由中国石油大学（北京）外国语学院刘慧，山东大学医学院李泽群、高会杰、梁本甲，外语学院郑红、陈洁、孙惠生、杨子婷翻译。
